Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers.
Saini SK, Ørskov AD, Bjerregaard AM, Unnikrishnan A, Holmberg-Thydén S, Borch A, Jensen KV, Anande G, Bentzen AK, Marquard AM, Tamhane T, Treppendahl MB, Gang AO, Dufva IH, Szallasi Z, Ternette N, Pedersen AG, Eklund AC, Pimanda J, Grønbæk K, Hadrup SR. Saini SK, et al. Among authors: holmberg thyden s. Nat Commun. 2020 Nov 9;11(1):5660. doi: 10.1038/s41467-020-19464-8. Nat Commun. 2020. PMID: 33168830 Free PMC article.
Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies.
Saini SK, Holmberg-Thydén S, Bjerregaard AM, Unnikrishnan A, Dorfmüller S, Platzbecker U, Tirado-Gonzalez I, Bönig H, El Fassi D, Grønbæk K, Pimanda J, Medyouf H, Hadrup SR. Saini SK, et al. Among authors: holmberg thyden s. Leukemia. 2022 Nov;36(11):2734-2738. doi: 10.1038/s41375-022-01705-y. Epub 2022 Oct 8. Leukemia. 2022. PMID: 36209321 Free PMC article. No abstract available.
Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.
Holmberg-Thydén S, Dufva IH, Gang AO, Breinholt MF, Schejbel L, Andersen MK, Kadivar M, Svane IM, Grønbæk K, Hadrup SR, El Fassi D. Holmberg-Thydén S, et al. Cancer Immunol Immunother. 2022 Feb;71(2):433-444. doi: 10.1007/s00262-021-02993-6. Epub 2021 Jul 4. Cancer Immunol Immunother. 2022. PMID: 34218294 Free PMC article. Clinical Trial.
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. O'Connell CL, et al. Among authors: holmberg thyden s. Clin Cancer Res. 2022 Dec 15;28(24):5306-5316. doi: 10.1158/1078-0432.CCR-22-1810. Clin Cancer Res. 2022. PMID: 36222848 Free PMC article. Clinical Trial.